Novacyt Stock

Novacyt Market capitalization

The The market capitalization of Novacyt (ALNOV.PA) as of Aug 21, 2026 is 25.06 M GBP. In the previous year, The market capitalization was 25.06 M GBP — a change of 0.00% (lower).

Market capitalization

25.06 MGBP

YoY

0.00%

Last updated:

In 2026, Novacyt's market cap stood at 25.06 M GBP, a 0.00% increase from the 25.06 M GBP market cap in the previous year.

The Novacyt Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Capitalization (undefined GBP)
Date
Market Capitalization (undefined GBP)
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
YEARMarket Capitalization (undefined GBP)
2027 est -
2026 est -
2025 est -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Novacyt's Market Capitalization

Novacyt's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Novacyt's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Novacyt's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Novacyt’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Novacyt stock

The market capitalization of Novacyt is 25.06 M GBP in 2026.

The market capitalization of Novacyt changed from 25.06 M GBP to 25.06 M GBP, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Novacyt since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's GBP, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' GBP varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Novacyt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Novacyt

All Key Metrics — Novacyt